Mini-Oral
T-DXd
ESMO IO 2024 | December 11-13, 2024
Lung Cancer
Trastuzumab deruxtecan (T-DXd) and pembrolizumab in immuno-oncology (IO)-naive HER2-expressing or HER2-mutant non-small cell lung cancer (NSCLC): Interim analysis of a phase Ib study
Antoine Italiano